<< Top 10 U.S.hospitals prefer Arctic Sun temperature management system | Ceragenix awarded $2.87M NIH grant to develop a drug for treating Clostrdium difficile and Shigella >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Filipino | Русский | Svenska | Polski

Dana-Farber Cancer Institute reaches milestone: $1 billion raised in campaign

Published on September 9, 2009 at 6:58 AM · No Comments

Dana-Farber Cancer Institute today announced it has reached its $1 billion Mission Possible: The Dana-Farber Campaign to Conquer Cancer fundraising goal one year early. The first hospital in New England to set and reach a $1 billion campaign goal, Dana-Farber will continue to raise funds for campaign priorities until Sept. 30, 2010, when the campaign was scheduled to end.

Philanthropy plays a critical role in advancing adult and pediatric cancer research and care at Dana-Farber. The Mission Possible campaign has created new avenues of research and new treatment options, but more work remains to be done, according to Institute officials. Dana-Farber is committed to continue fundraising through the end of the campaign and beyond until the promise of personalized medicine is available for each patient.

“We look upon the $1 billion raised to date as a significant milestone in the campaign,” said Josh Bekenstein, co-chair of the Mission Possible campaign and a managing director of Bain Capital, LLC. “We will continue to fundraise aggressively because cancer will not cease to exist when this campaign ends next year. There is much more critical work to be done and we need to remain committed to this important mission into the future.”

Larry Lucchino, president and CEO of the Boston Red Sox and co-chair of the Mission Possible campaign, added, “It has been my good fortune to be associated with Dana-Farber as a patient twice and as part of the leadership team for its current fundraising effort. Dana-Farber has proven over and over that cancer can be conquered. I am living proof of that. We need to continue to support Dana-Farber so that, some day, all patients can stand up and tell their stories of survival.”

The size and scope of the campaign reflect the growth of Dana-Farber during the last decade. Between 2001 and 2008, outpatient visits and infusions at Dana-Farber more than doubled, from nearly 128,000 to more than 264,000. The number of clinical trials available to Dana-Farber patients increased nearly 80 percent, from 409 trials to 735.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading